Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00252798
Status:
COMPLETED
Last Update Posted:
2007-12-19
First Post:
2005-11-01
Brief Title:
ZD1839 Iressa and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase I Trial to Evaluate ZD1839Iressa and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2007-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the trial is to determine the Maximum tolerated dose if any of the combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray Gy irradiation and up to 45 mgm2 paclitaxel
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1839IL0073 | None | None | None |